Boston Scientific (BSX) closed the most recent trading day at $42.04, moving +1.11% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.47% for the day. At the same time, the Dow added 0.1%, and the tech-heavy Nasdaq lost 1.25%.
Shares of the medical device manufacturer witnessed a loss of 7.52% over the previous month, trailing the performance of the Medical sector with its loss of 3.97%, and the S&P 500's gain of 1.15%.
Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on October 28, 2026. The company is forecasted to report an EPS of $0.76, showcasing a 1.33% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $5.17 billion, showing a 2.12% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.25 per share and a revenue of $21.17 billion, signifying shifts of +6.21% and +5.45%, respectively, from the last year.
Investors might also notice recent changes to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.3% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 12.78. This expresses a discount compared to the average Forward P/E of 19.24 of its industry.
We can also see that BSX currently has a PEG ratio of 1. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 98, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).